CTGLF3 inhibitors represent a specialized class of chemical compounds designed to selectively modulate the activity of a protein within the Cathepsin-like Granzyme Family 3 (CTGLF3). This protein family is characterized by its involvement in various cellular processes, including immune responses and intracellular proteolysis. The inhibitors developed for CTGLF3 exhibit a distinct chemical structure that allows them to interact selectively with specific binding sites on the CTGLF3 protein, thereby influencing its molecular activities at the cellular level. This tailored design is crucial for ensuring a high degree of specificity, minimizing unintended effects on other cellular components or proteins within the broader cathepsin-like granzyme family.
The mechanism of action of CTGLF3 inhibitors involves disrupting the normal functioning of the CTGLF3 protein, potentially impacting cellular processes such as immune surveillance and proteolytic cascades. The selectivity of these inhibitors is vital to avoid interference with other closely related cathepsin-like granzymes or cellular pathways. As researchers delve into the complexities of immune regulation and intracellular proteolysis, CTGLF3 inhibitors serve as valuable tools, allowing for the investigation of the precise molecular mechanisms governed by CTGLF3. The study of this chemical class contributes to a deeper understanding of the role played by CTGLF3 in cellular physiology, offering insights into its potential functions within the intricate networks that regulate immune responses and protein degradation. Overall, the exploration of CTGLF3 inhibitors provides a platform for advancing our understanding of the molecular landscape surrounding this specific member of the cathepsin-like granzyme family.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds to DNA and inhibits RNA polymerase, which can decrease mRNA synthesis for various genes, potentially including AGAP6. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein elongation, potentially reducing AGAP6 protein levels. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that is essential for protein synthesis and cell growth, which could result in downregulation of AGAP6 expression. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates DNA and inhibits topoisomerase II, leading to DNA damage and potentially affecting gene expression patterns. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C forms cross-links in DNA, which can inhibit DNA replication and transcription, potentially reducing AGAP6 expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits topoisomerase I, leading to DNA damage and possibly altered transcription of genes such as AGAP6. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide inhibits topoisomerase II, causing DNA strand breaks and could lead to changes in gene expression, including AGAP6. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect various signaling pathways and may result in decreased expression of certain proteins. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine can raise the pH of endosomes and lysosomes, affecting protein degradation and possibly altering levels of AGAP6. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide has been shown to inhibit the transcription of various genes by affecting RNA polymerase II activity, potentially impacting AGAP6 expression. | ||||||